Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Safety and Efficacy Clinical Trial

Official title:

An Open-Label Phase 1 Dose Exploration Study of JWCAR129, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04677452
• Other study ID #: JWCAR129
• Status: Recruiting
• Phase: Phase 1
• Start date: December 2020
• Est. completion date: December 2024

Study information

• Verified date: December 2020
• Source: The First Affiliated Hospital of Soochow University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, Phase 1 dose exploration study to evaluate the safety and tolerability and to determine recommended Phase 2 dose(s) of JWCAR129, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 2024
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years old and above.

2. Signed the Informed Consent Form.

3. Diagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Subjects must have received at least 3 prior anti-myeloma treatment regimens (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen). Subjects must be refractory to the last anti-myeloma treatment regimen prior to entering the study.

1. Autologous hematopoietic stem cell transplantation.

2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination. Subjects must have undergone at least 2 consecutive cycles of treatment for each regimen unless progressive disease was the best response to the regimen.

3. Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy. Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible; the reason for not receiving treatment must be clearly documented in the case report form.

4. Subjects must have measurable disease.

5. Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required).

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

7. Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function

Exclusion Criteria:

1. Subjects with known active or history of CNS involvement by malignancy

2. Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis

3. History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.

4. Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])

5. Prior CAR T-cell or other genetically-modified T-cell therapy

6. Prior treatment with a BCMA-targeted agent

7. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

8. Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JWCAR129 infusion.

9. History of any of the following cardiovascular conditions within 6 months of initial screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease

10. History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study

11. Allogeneic hematopoietic stem cell transplantation.

Related Conditions & MeSH terms

• Safety and Efficacy

Intervention

Biological:
• JWCAR129
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).

Locations

Country	Name	City	State
China	First Affiliated Hospital, Soochow University	Suzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicities (DLTs)	Proportion of subjects with adverse events meeting DLT criteria	28 days
Primary	Incidence and severity of adverse events	Proportion of subjects with adverse events overall and by severity grade	2 years
Primary	Incidence and severity of clinically significant laboratory abnormalities	Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade	2 years
Secondary	Cmax	Maximum concentration (Cmax) of JWCAR129 in the blood	2 years
Secondary	Tmax	Time to maximum concentration (Tmax) of JWCAR129 in the blood	2 years
Secondary	AUC	Area under the concentration vs time curve (AUC) of JWCAR129 in the blood	2 years
Secondary	Duration of persistence	Duration of persistence of JWCAR129 CAR T cells in the blood	2 years
Secondary	Overall response rate	Proportion of subjects with a partial response (PR) or better by IMWG criteria	2 years
Secondary	CR rate	Proportion of subjects with a CR by IMWG criteria	2 years